Efficacy of dupilumab reveals therapeutic target for IgG4-related disease: simultaneous control of inflammation and fibrosis

Volume: 81, Issue: 3, Pages: e50 - e50
Published: Feb 7, 2020
Abstract
We read with great interest the article from Simpson et al on the clinical efficacy of dupilumab in a patient with IgG4-related disease (IgG4-RD).1 Glucocorticoid is currently the first-line induction therapy for IgG4-RD.2 Since it generally suppresses acquired immune cells, we could not know the therapeutic targets in IgG4-RD. So far, the efficacy of rituximab, targeting B cells, has been discussed,3 but we reconfirm that type 2 helper T (Th2)...
Paper Details
Title
Efficacy of dupilumab reveals therapeutic target for IgG4-related disease: simultaneous control of inflammation and fibrosis
Published Date
Feb 7, 2020
Volume
81
Issue
3
Pages
e50 - e50
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.